MX2018004440A - Composiciones de silicato de zirconio de uso prolongado y metodos de uso de las mismas. - Google Patents

Composiciones de silicato de zirconio de uso prolongado y metodos de uso de las mismas.

Info

Publication number
MX2018004440A
MX2018004440A MX2018004440A MX2018004440A MX2018004440A MX 2018004440 A MX2018004440 A MX 2018004440A MX 2018004440 A MX2018004440 A MX 2018004440A MX 2018004440 A MX2018004440 A MX 2018004440A MX 2018004440 A MX2018004440 A MX 2018004440A
Authority
MX
Mexico
Prior art keywords
zirconium silicate
methods
silicate compositions
extended
lead content
Prior art date
Application number
MX2018004440A
Other languages
English (en)
Spanish (es)
Inventor
Jeffrey Keyser Donald
F Guillem Alvaro
Original Assignee
Zs Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58227650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018004440(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zs Pharma Inc filed Critical Zs Pharma Inc
Publication of MX2018004440A publication Critical patent/MX2018004440A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/02—Processes using inorganic exchangers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/14—Base exchange silicates, e.g. zeolites
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B39/00—Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites; Their preparation; After-treatment, e.g. ion-exchange or dealumination
    • C01B39/02—Crystalline aluminosilicate zeolites; Isomorphous compounds thereof; Direct preparation thereof; Preparation thereof starting from a reaction mixture containing a crystalline zeolite of another type, or from preformed reactants; After-treatment thereof
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B39/00—Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites; Their preparation; After-treatment, e.g. ion-exchange or dealumination
    • C01B39/02—Crystalline aluminosilicate zeolites; Isomorphous compounds thereof; Direct preparation thereof; Preparation thereof starting from a reaction mixture containing a crystalline zeolite of another type, or from preformed reactants; After-treatment thereof
    • C01B39/06—Preparation of isomorphous zeolites characterised by measures to replace the aluminium or silicon atoms in the lattice framework by atoms of other elements, i.e. by direct or secondary synthesis
    • C01B39/08—Preparation of isomorphous zeolites characterised by measures to replace the aluminium or silicon atoms in the lattice framework by atoms of other elements, i.e. by direct or secondary synthesis the aluminium atoms being wholly replaced
    • C01B39/085—Group IVB- metallosilicates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
    • C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/60—Particles characterised by their size
    • C01P2004/61—Micrometer sized, i.e. from 1-100 micrometer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Geology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2018004440A 2015-10-14 2016-10-10 Composiciones de silicato de zirconio de uso prolongado y metodos de uso de las mismas. MX2018004440A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/883,428 US9592253B1 (en) 2015-10-14 2015-10-14 Extended use zirconium silicate compositions and methods of use thereof
PCT/US2016/056286 WO2017066128A1 (en) 2015-10-14 2016-10-10 Extended use zirconium silicate compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2018004440A true MX2018004440A (es) 2018-07-06

Family

ID=58227650

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004440A MX2018004440A (es) 2015-10-14 2016-10-10 Composiciones de silicato de zirconio de uso prolongado y metodos de uso de las mismas.

Country Status (19)

Country Link
US (4) US9592253B1 (https=)
EP (1) EP3362456A4 (https=)
JP (1) JP6546700B2 (https=)
KR (1) KR102667566B1 (https=)
CN (2) CN108137620B (https=)
AR (1) AR106369A1 (https=)
AU (1) AU2016338753C1 (https=)
CA (1) CA3000950C (https=)
CL (1) CL2018000916A1 (https=)
CR (1) CR20180276A (https=)
EA (2) EA202091273A1 (https=)
HK (1) HK1254808A1 (https=)
IL (1) IL258478B (https=)
MX (1) MX2018004440A (https=)
MY (1) MY187088A (https=)
PH (1) PH12018500786B1 (https=)
TW (1) TWI742004B (https=)
WO (1) WO2017066128A1 (https=)
ZA (1) ZA201803095B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2673237T2 (sl) 2011-02-11 2025-12-31 Zs Pharma, Inc Uporaba cirkonijevega silikata v zdravljenju hiperkalemije
US9592253B1 (en) * 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
WO2019092179A1 (en) * 2017-11-10 2019-05-16 Sandoz Ag Pharmaceutical compositions comprising zs-9
BR112021017791A2 (pt) 2019-03-13 2022-02-01 Astrazeneca Ab Agentes de ligação ao potássio para uso em pacientes em hemodiálise
CN117342570B (zh) * 2023-09-04 2026-02-10 杭州国瑞生物科技有限公司 一种环硅酸锆钠的a晶型及其制备方法
CN117735564B (zh) * 2023-12-19 2025-12-19 杭州国瑞生物科技有限公司 一种环硅酸锆钠的b晶型及其制备方法与应用
CN120172420B (zh) * 2025-03-21 2025-12-23 时森海(杭州)医药科技有限公司 控制粒径分布的环硅酸锆钠及其制备方法
CN120984211A (zh) * 2025-06-13 2025-11-21 时森海(杭州)医药科技有限公司 生产环硅酸锆钠的反应器和方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE21224E (en) 1939-10-03 Coherent zirconium silicates
US2809943A (en) * 1952-09-11 1957-10-15 Dow Chemical Co Weighted ion exchange resin granules and method of making same
US3492092A (en) * 1966-04-04 1970-01-27 Chem Separations Corp Ion exchange process for treating crude mineral solutions
US3947279A (en) 1971-12-23 1976-03-30 Owens-Illinois, Inc. Thermally crystallizable glasses possessing precision controlled crystallization and flow properties and process of producing same
US4581141A (en) 1978-02-27 1986-04-08 Purdue Research Foundation Dialysis material and method for removing uremic substances
FR2444005A1 (fr) 1978-12-15 1980-07-11 Ugine Kuhlmann Procede industriel de fabrication en semi-continu de zeolithe a
US4943545A (en) 1987-06-08 1990-07-24 Mobil Oil Corporation Activation of zeolites
US5015453A (en) 1989-04-28 1991-05-14 W. R. Grace & Co.-Conn. Crystalline group IVA metal-containing molecular sieve compositions
US5099737A (en) 1991-02-22 1992-03-31 Curletto Giorgio F Double chambered bassboard housing for electronic M.I.D.I. accordion with retractable keyboard
US5338527A (en) 1992-08-20 1994-08-16 Uop Zirconium silicate composition, method of preparation and uses thereof
ES2092334T5 (es) 1992-10-28 2003-01-16 Ineos Silicas Ltd Silices.
US5518707A (en) 1994-10-24 1996-05-21 Uop Metallo germanates
IT1283284B1 (it) 1996-03-21 1998-04-16 Eniricerche Spa Zeolite ers-10 e procedimento per la sua preparazione
FR2750893B1 (fr) 1996-07-12 1998-10-30 Elf Aquitaine Procede de synthese de zeolithe avec agitation homogene du milieu, dispositif et application
US5891417A (en) 1997-04-08 1999-04-06 Uop Llc Zirconium silicate and zirconium germanate molecular sieves and process using the same
US5888472A (en) 1997-04-08 1999-03-30 Uop Llc Zirconium silicate molecular sieves and process using the same
CA2268888A1 (en) 1997-05-12 1998-11-19 Itsuki Uehara Separator for battery and alkali secondary battery using the same
US6007790A (en) 1998-08-13 1999-12-28 Uop Llc Family of microporous indium silicate compositions
US6099737A (en) 1999-03-29 2000-08-08 Uop Llc Process for removing toxins from blood using zirconium metallate or titanium metallate compositions
US6332985B1 (en) 1999-03-29 2001-12-25 Uop Llc Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
US7041274B2 (en) 1999-10-22 2006-05-09 Intevep, S.A. Aluminosilicate compositions, preparation and use
US20020061521A1 (en) 2000-01-31 2002-05-23 Rosen Craig A. Nucleic acids, proteins, and antibodies
US6379641B1 (en) 2000-05-01 2002-04-30 Uop Llc Microporous rare earth silicates and method of producing same
US6596254B1 (en) 2000-06-12 2003-07-22 Sandia Corporation Niobate-based octahedral molecular sieves
AU2002242103A1 (en) 2001-02-06 2002-08-19 Ash Medical Systems, Inc. Monovalent-selective cation exchangers as oral sorbent therapy
US6579460B1 (en) 2001-03-13 2003-06-17 Uop Llc Process and composition for removing toxins from bodily fluids
US6814871B1 (en) 2001-07-13 2004-11-09 Uop Llc Process for removing pollutants from aqueous streams
US6689335B1 (en) 2002-12-19 2004-02-10 Eastman Kodak Company Silver ion sequester and release agent
KR100804360B1 (ko) 2003-12-15 2008-02-15 아사히 가세이 케미칼즈 가부시키가이샤 다공성 성형체 및 그의 제조 방법
US8192758B2 (en) * 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
BRPI0509365B8 (pt) 2004-03-30 2021-05-25 Ilypsa Inc composição farmacêutica, kit farmacêutico, e, uso da referida composição
EP2599547B1 (en) 2004-12-28 2019-03-27 Renal Solutions, Inc. Method of synthesizing zirconium phosphate particles
KR101005388B1 (ko) 2005-06-14 2010-12-30 아사히 가세이 케미칼즈 가부시키가이샤 수처리 장치 및 수처리 방법
BRPI0616603A2 (pt) 2005-09-30 2012-12-25 Ilypsa Inc mÉtodo para preparar um compàsito de nécleo-envoltàrio, e para a manufatura de um medicamento, composiÇço farmacÊutica, e, uso da mesma
WO2007041569A1 (en) 2005-09-30 2007-04-12 Ilypsa, Inc. Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
US7297318B2 (en) * 2005-11-17 2007-11-20 J.M. Huber Corporation Method of removing heavy metals from silicate sources during silicate manufacturing
US7201885B1 (en) * 2005-11-17 2007-04-10 J.M. Huber Corporation Method of removing heavy metals from silicate sources during silicate manufacturing
US8367112B2 (en) 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
WO2007127390A2 (en) 2006-04-28 2007-11-08 Biolife, L.L.C. Materials and methods for wound treatment
KR101002571B1 (ko) 2007-01-03 2010-12-17 주식회사 인실리코텍 다공성 금속-유기 골격 구조를 갖는 배위중합체 결정 및이의 제조방법
ES2304890B1 (es) 2007-04-03 2009-10-30 Universidad De Zaragoza Procedimiento de obtencion de esferas de titanosilicato.
EP3138822B1 (en) 2008-02-26 2023-07-26 Corning Incorporated Fining agents for silicate glasses
PT2365988E (pt) 2008-08-22 2015-10-22 Relypsa Inc Polímeros de permuta iónica reticulados, composições e uso no tratamento da hipercalemia
WO2010022381A1 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
US8865121B2 (en) 2009-06-18 2014-10-21 Basf Se Organotemplate-free synthetic process for the production of a zeolitic material
GB0913525D0 (en) * 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
US20120070468A1 (en) 2010-09-16 2012-03-22 Uop Llc Removal of toxins from gastrointestinal fluids
SI2673237T2 (sl) * 2011-02-11 2025-12-31 Zs Pharma, Inc Uporaba cirkonijevega silikata v zdravljenju hiperkalemije
EP2694437B1 (en) 2011-04-08 2020-10-21 Basf Se Process for producing acylation catalyst
US9527751B2 (en) 2011-11-11 2016-12-27 Basf Se Organotemplate-free synthetic process for the production of a zeolitic material of the CHA-type structure
US20130202524A1 (en) 2012-02-06 2013-08-08 Basf Se Iron- And Copper-Containing Zeolite Beta From Organotemplate-Free Synthesis And Use Thereof In The Selective Catalytic Reduction Of NOx
US9475041B2 (en) 2012-04-24 2016-10-25 Basf Se Zeolitic materials and methods for their preparation using alkenyltrialkylammonium compounds
CN104968336A (zh) * 2012-07-11 2015-10-07 Zs制药公司 用于治疗高钙血症患者高钾血症的微孔硅酸锆以及用于治疗高钾血症的改进的含钙组合物
CN104797263B (zh) * 2012-10-22 2018-02-09 Zs制药公司 用于治疗高钾血症的微孔硅酸锆
BR112015025438B1 (pt) * 2013-04-05 2022-06-07 Zs Pharma, Inc Uso de um silicato de zircônio
CA2929978C (en) * 2013-11-08 2021-11-30 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
CA2933048A1 (en) * 2013-12-10 2015-06-18 ZS Pharma, Inc. Zirconium silicate for treating hyperkalemia without co-administering lithium
US9592253B1 (en) * 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof

Also Published As

Publication number Publication date
IL258478B (en) 2020-09-30
AU2016338753C1 (en) 2019-08-08
PH12018500786A1 (en) 2018-10-29
ZA201803095B (en) 2019-11-27
US20190365800A1 (en) 2019-12-05
US12582673B2 (en) 2026-03-24
PH12018500786B1 (en) 2022-09-07
EP3362456A4 (en) 2019-05-15
AR106369A1 (es) 2018-01-10
CL2018000916A1 (es) 2018-08-17
CA3000950C (en) 2023-10-31
CR20180276A (es) 2018-09-19
AU2016338753A1 (en) 2018-04-12
KR20180067614A (ko) 2018-06-20
TWI742004B (zh) 2021-10-11
JP6546700B2 (ja) 2019-07-17
CN108137620A (zh) 2018-06-08
EP3362456A1 (en) 2018-08-22
US20240009229A1 (en) 2024-01-11
NZ740931A (en) 2024-12-20
US10300087B2 (en) 2019-05-28
US9592253B1 (en) 2017-03-14
US20170151279A1 (en) 2017-06-01
CN113143958A (zh) 2021-07-23
WO2017066128A1 (en) 2017-04-20
HK1254808A1 (zh) 2019-07-26
MY187088A (en) 2021-08-30
JP2018530596A (ja) 2018-10-18
CA3000950A1 (en) 2017-04-20
AU2016338753B2 (en) 2019-04-18
US11738044B2 (en) 2023-08-29
EA202091273A1 (ru) 2021-02-03
CN108137620B (zh) 2021-05-18
EA035890B1 (ru) 2020-08-27
TW201717972A (zh) 2017-06-01
IL258478A (en) 2018-05-31
EA201890875A1 (ru) 2018-11-30
BR112018007189A2 (en) 2018-10-16
KR102667566B1 (ko) 2024-05-22

Similar Documents

Publication Publication Date Title
CL2018000916A1 (es) Composiciones de silicato de zirconio de uso prolongado y métodos de uso de las mismas
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
UY35813A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CR20180069A (es) Derivados de la sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b
MX2017001512A (es) Compuestos activos hacia bromodominios.
MX380866B (es) Composiciones y métodos para modular la expresión del factor b del complemento.
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
BR112017002214A2 (pt) composto de fórmula (i), composição farmacêutica e usos de um composto
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
AR100453A1 (es) Composiciones para el cuidado oral que contienen polietilenglicol para estabilidad física
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
EA201890828A1 (ru) Оптимизированная таблетка с высокой дозой активного соединения, содержащая месалазин
MX373636B (es) Compuestos de azetidiniloxifenilpirrolidina.
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
BR112017024126A2 (pt) composições farmacêuticas e uso das mesmas
CR20170498A (es) 2-tiopirimidinonas
AR097111A1 (es) Combinación y método para la administración a un animal
UY35600A (es) "composiciones farmacéuticas que comprenden compuestos derivados de triazolopiridina y métodos para prepararlas"
AR111017A1 (es) Sal hemisulfato de un compuesto nucleotídico para el tratamiento del virus de la hepatitis c
CR20160175A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
AR101407A1 (es) Composiciones para el tratamiento de superficies duras

Legal Events

Date Code Title Description
GD Licence granted
FG Grant or registration